10:02 AM EST, 01/10/2025 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) reported Friday preliminary Q4 revenue of $130.8 million, up 40% year over year.

Analysts polled by FactSet expected $128.6 million.

The company said it expects full-year 2025 revenue between $540 million and $560 million. Analysts polled by FactSet expect $536.4 million.

Shares of the company fell 4.5% in recent trading.

Price: 7.69, Change: -0.36, Percent Change: -4.47